PT Kimia Farma TbkISX:KAEF +0.90%56 Altman Z-Score is 0.18 as of Jul. 03, 2026, which is 88% below its 10-year median of 1.49. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.77 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 117 Medical Distribution companies, PT Kimia Farma Tbk ranks worse than 89.74% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 0.18 is in distress zone. This implies bankruptcy possibility in the next two years.
PT Kimia Farma Tbk has a Altman Z-Score of 0.18, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for PT Kimia Farma Tbk's Altman Z-Score or its related term are showing as below:
ISX:KAEF'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.1 Med: 1.49 Max: 6.19
Current: 0.18
During the past 13 years, PT Kimia Farma Tbk's highest Altman Z-Score was 6.19. The lowest was -0.10. And the median was 1.49.
PT Kimia Farma Tbk (ISX:KAEF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
PT Kimia Farma Tbk Altman Z-Score Related Terms
PT Kimia Farma Tbk Altman Z-Score Historical Data
* Premium members only.
The historical data trend for PT Kimia Farma Tbk's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:KAEF vs MCK, CAH, COR: Altman Z-Score Comparison
For the Medical Distribution subindustry, PT Kimia Farma Tbk's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Tbk Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Tbk's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
PT Kimia Farma Tbk's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
-0.1236
+
1.4
*
-0.3759
+
3.3
*
0.027
+
0.6
*
0.2159
+
1.0
*
0.6328
=
0.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Trailing Twelve Months (TTM) ended in Mar. 2026: Total Assets was Rp14,358,871 Mil. Total Current Assets was Rp4,316,463 Mil. Total Current Liabilities was Rp6,091,613 Mil. Retained Earnings was Rp-5,398,173 Mil. Pre-Tax Income was 127955.495 + -223745.331 + -94331.06 + 7143.65 = Rp-182,977 Mil. Interest Expense was -110154.762 + -221526.832 + -115647.001 + -123998.065 = Rp-571,327 Mil. Revenue was 2030649.486 + 2215116.743 + 2638862.719 + 2201140.777 = Rp9,085,770 Mil. Market Cap (Today) was Rp2,482,699 Mil. Total Liabilities was Rp11,499,584 Mil.
* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.
PT Kimia Farma Tbk (ISX:KAEF) has a Altman Z-Score of 0.18 as of Jul. 03, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on PT Kimia Farma Tbk and its competitors. This is 88% below median its historical median of 1.49. According to the industry distribution chart, PT Kimia Farma Tbk ranks #105 out of 117 companies in the Medical Distribution industry, placing it in the top 89.7%.
Is PT Kimia Farma Tbk's Altman Z-Score too high?
PT Kimia Farma Tbk's current Altman Z-Score of 0.18 is 88% below median its 10-year median of 1.49. The Medical Distribution industry median Altman Z-Score is 2.49. PT Kimia Farma Tbk's value of 0.18 is 92.8% below this industry median. Based on the distribution chart, PT Kimia Farma Tbk ranks #105 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's Altman Z-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Tbk ranks #105 out of 117 companies for Altman Z-Score. This places PT Kimia Farma Tbk in the lower half of its industry. The industry median Altman Z-Score is 2.49. PT Kimia Farma Tbk's value of 0.18 is 92.8% below this benchmark. While the company's 10-year median is 1.49 vs. the industry median of 2.49, PT Kimia Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.49, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Tbk's current Altman Z-Score of 0.18 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on PT Kimia Farma Tbk and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Tbk's current Altman Z-Score is 0.18, which is 88% below median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.77, compared to a current price of Rp446.00 — trading 23.3% below its estimated fair value. The current Altman Z-Score is 0.18, which is 88% below median its 10-year median of 1.49 and 92.8% below the Medical Distribution industry median of 2.49. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current Altman Z-Score is 0.18 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued.
The current stock price of Rp446.00 is trading 23.3% below its estimated GF Value™ of Rp581.77.
GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
Altman Z-Score: 0.18 (88% below median its 10-year median of 1.49)
GF Value™: Rp581.77 vs. price of Rp446.00 (23.3% below fair value)
Industry Position: 92.8% below the Medical Distribution median (#105 of 117)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score
Get the complete analysis for ISX:KAEF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
